TAKEDA PHARMACEUTICAL CO LTD
TAK · XNYSCIK 1395064fmd_0PMH94341VM7KDDJNYKRM02K9BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2016 to Mar 31, 2025, 9 periods
Latest annual · FY2025
Millions- Total revenues
- 4,581,551
- Gross profit
- 3,001,334
- Operating income
- 342,586
- Net income
- 107,928
- Free cash flow
- 856,387
Daily close · TAKIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions20.86 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +8.7%
- Revenue, 5 yearsFY2020 to FY2025
- +6.8%
- Net income, 5 yearsFY2020 to FY2025
- +19.5%
TAKEDA PHARMACEUTICAL CO LTD (TAK) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | ¥4.6 trillion | ¥4.3 trillion | +7.5% | 20-F 2025-06-25 · proof |
| Gross profit | ¥3 trillion | ¥2.8 trillion | +5.8% | 20-F 2025-06-25 · proof |
| Operating income | ¥342.6 billion | ¥214.1 billion | +60% | 20-F 2025-06-25 · proof |
| Net income | ¥107.9 billion | ¥144.1 billion | -25.1% | 20-F 2025-06-25 · proof |
| Cash from operating activities | ¥1.1 trillion | ¥716.3 billion | +47.6% | 20-F 2025-06-25 · proof |
| Free cash flow | ¥856.4 billion | ¥540.9 billion | +58.3% | 20-F 2025-06-25 · proof |
| Total assets | ¥14.2 trillion | ¥15.1 trillion | -5.7% | 20-F 2025-06-25 · proof |
| Total liabilities | ¥7.3 trillion | ¥7.8 trillion | -6.7% | 20-F 2025-06-25 · proof |
| Cash and cash equivalents | ¥385.1 billion | ¥457.8 billion | -15.9% | 20-F 2025-06-25 · proof |
| Total debt | ¥4.5 trillion | ¥4.8 trillion | -6.8% | 20-F 2025-06-25 · proof |
- What was TAKEDA PHARMACEUTICAL CO LTD (TAK)'s revenue in fiscal 2025?
- TAKEDA PHARMACEUTICAL CO LTD (TAK) reported revenue of ¥4.6 trillion for fiscal 2025 (the year ended Mar 31, 2025), against ¥4.3 trillion the year before (+7.5%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What was TAKEDA PHARMACEUTICAL CO LTD (TAK)'s gross profit in fiscal 2025?
- TAKEDA PHARMACEUTICAL CO LTD (TAK) reported gross profit of ¥3 trillion for fiscal 2025 (the year ended Mar 31, 2025), against ¥2.8 trillion the year before (+5.8%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What was TAKEDA PHARMACEUTICAL CO LTD (TAK)'s operating income in fiscal 2025?
- TAKEDA PHARMACEUTICAL CO LTD (TAK) reported operating income of ¥342.6 billion for fiscal 2025 (the year ended Mar 31, 2025), against ¥214.1 billion the year before (+60%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What was TAKEDA PHARMACEUTICAL CO LTD (TAK)'s net income in fiscal 2025?
- TAKEDA PHARMACEUTICAL CO LTD (TAK) reported net income of ¥107.9 billion for fiscal 2025 (the year ended Mar 31, 2025), against ¥144.1 billion the year before (-25.1%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What was TAKEDA PHARMACEUTICAL CO LTD (TAK)'s cash from operating activities in fiscal 2025?
- TAKEDA PHARMACEUTICAL CO LTD (TAK) reported cash from operating activities of ¥1.1 trillion for fiscal 2025 (the year ended Mar 31, 2025), against ¥716.3 billion the year before (+47.6%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What was TAKEDA PHARMACEUTICAL CO LTD (TAK)'s free cash flow in fiscal 2025?
- TAKEDA PHARMACEUTICAL CO LTD (TAK) reported free cash flow of ¥856.4 billion for fiscal 2025 (the year ended Mar 31, 2025), against ¥540.9 billion the year before (+58.3%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What are TAKEDA PHARMACEUTICAL CO LTD (TAK)'s total assets?
- As of Mar 31, 2025, TAKEDA PHARMACEUTICAL CO LTD (TAK) reported total assets of ¥14.2 trillion, against ¥15.1 trillion a year earlier (-5.7%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What are TAKEDA PHARMACEUTICAL CO LTD (TAK)'s total liabilities?
- As of Mar 31, 2025, TAKEDA PHARMACEUTICAL CO LTD (TAK) reported total liabilities of ¥7.3 trillion, against ¥7.8 trillion a year earlier (-6.7%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What are TAKEDA PHARMACEUTICAL CO LTD (TAK)'s cash and cash equivalents?
- As of Mar 31, 2025, TAKEDA PHARMACEUTICAL CO LTD (TAK) reported cash and cash equivalents of ¥385.1 billion, against ¥457.8 billion a year earlier (-15.9%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
- What is TAKEDA PHARMACEUTICAL CO LTD (TAK)'s total debt?
- As of Mar 31, 2025, TAKEDA PHARMACEUTICAL CO LTD (TAK) reported total debt of ¥4.5 trillion, against ¥4.8 trillion a year earlier (-6.8%). Source: the 20-F filed with the SEC on Jun 25, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:TAK&period_type=annual&limit=5"Information only, not investment advice.